Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1988
Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinoneP J Silver, R E Lepore, B O'Connor, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1989
Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pigA L Harris, M J Connell, E W Ferguson, et al.
Journal of Cardiovascular Pharmacology|September 1, 1994
Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582E D Pagani, R L Dundore, D C Bode, et al.
European Journal of Pharmacology|February 15, 1994
Pharmacological modulation of human cardiac Na+ channelsD S Krafte, K Davison, N Dugrenier, et al.
European Journal of Pharmacology|August 11, 1998
Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivoP J Silver, J P Moreau, E Denholm, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005R L Dundore, E D Pagani, D C Bode, et al.
European Journal of Pharmacology|November 16, 1993
Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of ratsR L Dundore, D M Clas, L T Wheeler, et al.
Journal of Cardiovascular Pharmacology|October 1, 1992
Hemodynamic and renal effects of the protein kinase inhibitor staurosporine in conscious ratsR L Dundore, A C Brousseau, P G Habeeb, et al.
European Journal of Pharmacology|October 10, 1996
Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivoL De Garavilla, E D Pagani, R A Buchholz, et al.
Pageof 7